[Asia Economy Reporter Minji Lee] NeoImmuneTech (Reg.S) announced on the 7th that it has received approval in Italy for a Phase 2 clinical trial plan involving the combination therapy of NT-I7 and Nivolumab, as well as Nivolumab monotherapy, targeting subjects with advanced or metastatic gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal cancer.
The company stated, "The purpose is to evaluate the therapeutic safety, tolerability, and efficacy of the combination therapy of NT-I7 and Nivolumab."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
